“Chang Yi Wang”的意思、由来-开放百科全书

2. Protein drugs including innovative monoclonal antibodies and long acting protein drugs, with first amongst them an Anti-CD4 antibody UB421 for treatment of HIV infection including potential for sustained viral suppression.

Dr. Wang is the founder of United Biomedical, Inc. (UBI) , headquartered in Hauppauge, New York, and its group of companies in Asia. She has served as chief scientific officer of UBI since its inception in December 1985, and as chairperson and chief executive officer of the UBI Group of companies since 1998. Dr. Wang is the author of more than 120 peer-reviewed scientific publications and she is the inventor of more than 100 patents to date. She has given various keynote and plenary lectures both nationally and internationally in the areas of Immunology, vaccination, immunotherapeutics and Infectious disease. She has also served on the scientific review committee for the Cooperative Research Partnerships for BioDefense and Allergy and Immunobiology programs funded and administered by the U.S. National Institutes of Health ( NIH) . In 2007, the New York Intellectual Property Law Association ( NYIPLA) presented Dr. Wang with the Inventor of the Year Award^[1]. In 2018, the Brain Mapping Foundation presented Dr. Wang with the Pioneer in Technology Award for her contribution in the development of therapeutic vaccines for the treatment of Neurodegenerative Diseases.

Early life and education

Dr. Wang was born in Taipei, Taiwan. She attended the prestigious Taipei First Girls' High School, where she first became aware of the double helix structure of DNA, which served as one of the primary motivators for her lifetime pursuit of biomedical sciences.

She graduated with honor from National Taiwan University in 1973, majoring in chemistry. Dr. Wang was the first Asian woman accepted into the graduate program at Rockefeller University in the United States, where in 1979 she received a Ph.D. degree with dual specialization in Biochemistry and Immunology. She joined the Memorial Sloan Kettering Cancer Center from 1979 to 1985, becoming its youngest faculty member, principal investigator and head of the molecular immunology laboratory, endowed by the Arthur J. and Leslie Levine Fund.

Career in immunology and entrepreneurship in the biomedical industry

Dr. Wang has been a pioneer in advocating “immunology as a secret weapon in medicine,” combined with personal motivation for developing medical interventions via application of basic biomedical sciences. Her first such achievements in terms of immunological applications of synthetic peptides were antibody screening immunoassays employing highly optimized synthetic viral peptide antigens. The first involved developing a synthetic peptide-based HIV 1, and later an HIV 1,2 diagnostic test for blood screening, both of which received U.S. Food and Drug Administration approval, in 1989 and 1996, respectively. These tests were subsequently recognized by the WHO as being suitable for worldwide use. Her other contributions in this area include synthetic peptide-based blood screening diagnostics for HTLV I/II and the Hepatitis C virus (HCV), which received CE certification and was sold in the global market through Organon Teknika /Biomerieux since 1991, as well as screening diagnostics for the SARS coronavirus, and diagnostic tests for the differentiation of infected vs. vaccinated animals for foot and mouth disease.

Since 1992, she has received support and guidance from Dr. James D. Watson, the co-discoverer of the double-helix DNA structure and a board member of United Biomedical, Inc at the time, in the courageous pursuit of many challenging vaccine and immunotherapy programs employing designer synthetic peptides.

At the invitation of the Taiwanese government (Ministry of Economic Affairs and National Development Fund), Dr. Wang, representing UBI US, established UBI-Asia as a joint venture with Taiwanese government Agencies. Upon establishing UBI Asia in Taiwan in 1999, Dr. Wang’s mission was to position UBI Asia as the center of excellence in the protein and monoclonal antibody drug-development area. In line with her mission, she assembled and led a team of scientists and industrial experts to ensure the establishment of an integrated platform technology and a rich pipeline of high-impact products. The UBI-421 monoclonal antibody, first in this pipeline and also a brainchild of hers with a series of issued and pending patents, is in phase III trials for HIV treatment as a HAART substitution, as well as other applications including functional cure. Many other products are currently in various preclinical and clinical stages of development. In order to fully develop and commercialize these products, two companies, United BioPharma and UBI Pharma, were spun off from UBI Asia to allow dedicated resources for commercialization of the respective pipelines of monoclonal antibodies and long-acting protein drugs. The two companies have also established respective state-of-the-art manufacturing facilities at both Hsin Chu, Taiwan and Yangzhou, China to prepare for commercialization of these innovative protein drugs worldwide.

Challenging Chiron’s broad HCV epitope claims and worldwide HCV patents

Dr. Wang’s patent for diagnostic Hepatitis C virus (HCV) peptide epitopes was the first such patent issued in the United States which was also subsequently licensed to Roche Diagnostics. Partnering with distributor Organon Teknika/Biomerieux, UBI’s peptide

antigen-based HCV blood-screening test was a success in Europe in the early 1990s. However, patent litigation ensued between

Chiron et al. and UBI et al. regarding Chiron’s broadly claimed HCV epitope patent. Six Nobel laureates served as expert witnesses and judicial advisors in the UK court to dispute the validity of the broadly claimed Chiron HCV epitope/peptide patent. Following years of litigation and Dr. Wang’s valiant efforts in putting forth technical arguments challenging the validity of Chiron’s overly broad HCV epitope claims, UBI prevailed. In the year of 2000, the Technical Board of the European Patent Office invalidated all overly broad HCV epitope claims. Meanwhile, the UK’s Section 44 patent law was also repealed at the advice of a team of experts including patent barristers and judges setting a case for “lack of support can be used to attack the breadth of patent claims even after the patent is issued”. This result freed up valuable information derived from detailed RNA or DNA sequences for public research and follow-up inventions, finally allowing for worldwide use of the vast amount of Genomic sequence generated by the biomedical community.

Pioneering high precision designer peptide-based vaccines and immunotherapeutics as a new class of biologicals

For the past 25 years, Dr. Wang has dedicated herself to the discovery, design and development of a new class of biologicals comprising Immunotherapeutics and vaccines for the therapy and prevention of chronic and infectious diseases, and companion diagnostics for monitoring treatment and control of these diseases. The resultant peptide-based biologicals act by directing the immune system to specific functional target sites and have great potential in a wide range of therapeutic areas.

Under her direction, “UBITh”, a new platform technology in high precision peptide immunogen design for the development of innovative vaccines and immunotherapeutics, was established. Some examples include a site-specific UBITh amyloid-β vaccine and Tau vaccine for Alzheimer’s disease, a site-specific Alpha Synuclein vaccine for Parkinson’s disease, an IgE vaccine for allergic diseases, and others for multiple human and animal health applications, including an LHRH vaccine for boar taint removal via immunocastration, and vaccines against infections caused by Porcine circovirus, Porcine Reproductive and Respiratory Syndrome Virus, and Foot and mouth disease viruses. Validation for the UBITh vaccine

technology has been demonstrated by achieving the long-sought goal of producing a Synthetic peptide vaccine for Foot and mouth disease, selling over 3 billion doses since introduction in 2007 in China, the largest swine market.

First Asian female recipient of the NYIPLA Inventor of the Year Award

The New York Intellectual Property Law Association’s Inventor of the Year award recognizes an individual or group who, through inventive talents, has made worthwhile contributions to society by promoting “the progress of science and useful arts”. Dr. Chang Yi Wang was the 2007 recipient for her work on “UBITh peptide immunogens”. Dr. Wang’s work on synthetic peptide-based immunotherapeutics, vaccines, and diagnostics made her the first Asian female recipient of the prestigious award.

Recipient of the 2018 Pioneer in Technology Award given by the Brain Mapping Foundation

The Brain Mapping Foundation (BMF) is established for the purpose of facilitating multidisciplinary brain and spinal cord research, and expediting integration of cutting-edge technologies into the field of Neuroscience. Dr. Wang was the 2018 recipient for Pioneer in Technology Award given by the foundation for her cumulative work on the development of high precision endobody vaccines for the treatment of Neurodegenerative Diseases.

Personal life

Dr. Wang divides her time between the United States and Taiwan, actively engaged in R&D and business development activities in biomedical applications. Her husband, Nean Hu^[2] , devotes his time to UBI’s subsidiaries in Shanghai, China. She has one daughter, Mei Mei Hu, JD, who serves as co-CEO of United Biomedical Inc. (UBI) and CEO of United NeuroScience(UNS).

A Commemoration of Chang Yi Wang’s Mentors

In 1974, Chang Yi, already an astute organic chemist as a result of her undergraduate training at National Taiwan University, joined Dr. Merrifield’s laboratory at Rockefeller University as a

first-year Ph.D. student, learning the many facets of solid-phase peptide chemistry. Dr. Merrifield won the Nobel Prize in Chemistry in 1984 for his pioneering work in solid-phase peptide synthesis.

Chang Yi’s use of this synthetic tool for some of her inventions in immunological applications in diagnostics, vaccines and immunotherapeutics began in the mid ‘80s.

Dr. Kunkel, often referred to as “the father of immunopathology” was Chang Yi’s Ph.D. dissertation advisor from 1975 to 1979 at Rockefeller University. He trained Chang Yi as an investigator, teaching her how to master a few simple technologies and apply them to the most important subjects, and how an inquisitive mind can discover intriguing findings in an ignored corner that few can fathom.

Dr. Edelman, an American biologist who received his Ph.D. training at Dr. Kunkel’s laboratory, shared the 1972 Nobel Prize in Physiology or Medicine for work with Rodney R. Porter on the immune system. Specifically, the Nobel Prize was given for his discovery of the structure of antibody molecules. Dr. Edelman and his laboratory colleagues taught immunology and biochemistry classes at Rockefeller University and were instrumental in leading Chang Yi to the most exciting, yet then still primitive, field of immunology.

Dr. Steinman, a Canadian Immunologist and cell biologist, was one of the recipients of the 2011 Nobel Prize in Physiology or Medicine for his discovery of the dendritic cell and its role in adaptive immunity. He was the first teacher at the Rockefeller University to bring Chang Yi to the intriguing field of cellular immunology at a time when he was describing his EM finding of dendrite-like immune cells later known as the dendritic cells, critical for initiating the immune responses.

Dr. Good, regarded as a founder of modern immunology, was an American physician who performed the first successful human bone marrow transplant between persons who were not identical twins. Chang Yi was recruited immediately after receiving her Ph.D. degree as an independent Principal Investigator and Head of Laboratory of Molecular Immunology by Dr. Good, then president of the Sloan Kettering Institute of the Memorial Sloan Kettering Cancer Center (MSKCC) in Manhattan, the world’s largest cancer center.

Her work in the early ‘80s used specific monoclonal antibodies to define several critical lymphocyte surface markers (LEU1, LEU3, LEU4, LEU10, LEU13, LEU14 and the idiotypic leukemic T cell marker, also known as the T cell receptor).

Dr. Old was one of the founders and standard bearers of the field of cancer immunology. Chang Yi’s entry into the tumor immunology and cytokine fields originated from a collaboration with Dr. Old while at the MSKCC by characterizing a tumor necrosis factor defined by Dr. Old’s laboratory in the ‘70s found in mice serum. The cytokine was purified to homogeneity as a 17KD molecule before it was cloned by Cetus in 1983.

Monoclonal antibodies to cytokines including TNF-alpha, funding through a NCI contract, and other tumor-specific antigens—mostly heat-stable glycolipids—were developed in the mid-‘80s by Chang Yi’s laboratory for further clinical applications.

Selected scientific publications

1. Wang CY, Wong WW, Tsai HC, Chen YH, Kuo BS, Lynn S, Blazkova J, Clarridge KE, Su HW, Lin CY, Tseng FC, Lai A, Yang FH, Lin CH, Tseng W, Lin HY, Finstad CL, Wong-Staal F, Hanson CV, Chun TW, Liao MJ. Effect of anti-CD4 Antibody UB-421 on HIV-1 rebound after treatment interruption. New England Journal of Medicine. 2019 (in press)

2. Verma A, Yu HJ, Chen HC, Wang CY. Active Anti-Amyloid Immunotherapy with UB-311 Vaccine: Update on design and baseline data of a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study. Journal of Prevention of Alzheimer Disease. 2019 (in press)

(CGRP) and formulations thereof for prevention and treatment of migraine” US Provisional Application No. 62/787,102 (2018).

4. Wang CY. “Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunotherapy of diseases impacted by IL-6 dysregulation” US Provisional Application No. 62/786,192 (2018).

5. Wang CY. “Artificial promiscuous T helper cell epitopes as immune stimulators for synthetic peptide immunogens” US Provisional Application No. 62/782,253 (2018).

6. Wang CY. “Peptide immunogen constructs directed against dipeptide repeat proteins from C9ORF72” US Provisional Application No. 62/739,794 (2018).

7. Wang CY. et al., “Peptide immunogens and formulations thereof targeting membrane-bound IgE for treatment of IgE mediated allergic diseases” TW Patent Application 107147187 (2018) and WO Application No. PCT/US17/069174 (2017).

8. Wang CY. “Peptide immunogens of IL-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis” TW Patent Application 107144910 (2018) and WO Application No. PCT/US2018/065025 (2018).

9. Wang CY. “Artificial Promiscuous T helper cell epitopes that facilitate targeted antibody production with limited T cell inflammatory response” US Provisional Application No. 62/667,123 (2018).

10. Wang CY. “Tau peptide immunogen constructs” TW Patent Application 107138171 (2018) and WO Application No. PCT/US2018/057840 (2018).

11. Wang CY. “Peptide immunogens from the C-Terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies” TW Patent Application 107120762 (2018) and WO Application No. PCT/US2018/037938 (2018).

12. Wang CY, Wang, PN, Chiu MJ, Finstad CL, Lin F, Lynn S, Tai YH, Fang XD, Zhao K, Hung CH, Tseng Y, Peng WJ, Wang J, Yu CC, Kuo BS, Frohna PA. UB-311, a novel UBITh® amyloid-β peptide vaccine for mild Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2017, 3:262-272. Supplementary data related to this article can be found at: http://dx.doi.org/10.1016/j.trci.2017.03.005.

13. Chen HC, Wang PN, Chiu MJ, Huang CC, Chang CC, Yen TC, Lin KJ, Seibyl J, Hesterman J, Wang CY, Verma A. (2017, November). Low PET screen failure rate in the UB-311 phase 2A study enriched for ApoE4 carriers with mild cognitive deficit. Poster session presented (November 2017) at Clinical Trials of Alzheimer’s Disease, Boston, MA.

14. Verma A, Maruff P, Schembri A, Wang PN, Chiu MJ, Huang CC, Chang CC, Chen HC, Chang P, Wang CY. UB-311 active vaccine generates titers specific for Aβ oligomers and fibrils without evidence of ARIA-E or encephalopathy in a completed Phase 1 and an ongoing Phase 2a study in Alzheimer’s disease. Poster session presented (November 2017) at Clinical Trials of Alzheimer’s Disease, Boston, MA.

15. Wang CY, Wong WW, Tsai HC, Chen YH, Liao MJ, Lynn S. Poster Abstract 450LB: A Phase 2 Open-Label Trial of Antibody UB-421 Monotherapy as a Substitute for HAART. Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI), February 13-16, 2017, Seattle, WA.

16. Wang CY. “Treatment and Sustained Virologic Remission of HIV Infection by Antibodies to CD4 in HAART Stabilized Patients” TW Patent Application 106127443 (2017) and WO Application No. PCT/US2017/046668. (2017).

17. Wang CY and Peng WJ. “Immunogenic LHRH composition and use thereof in pigs” US Patent Application 15/329,154 (2017).

18. Wang CY. et al. “Immunoglobulin fusion proteins and use thereof” US Patent Application 15/002,396 (2016), TW Patent Application 105117815 (2016) and WO Patent Application PCT/US16/039615 (2016).

19. Wang CY. “Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer’s type” US Patent 9,102,752 (2015), US Patent Application 14/824,075 (2015), and WO Patent Application PCT/US13/37865 (2013).

20. Wang CY. “Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD)” US Patent Application 14/443,363 (2015), and WO Patent Application PCT/US2012/065386 (2012).

21. Wang CY. “Synthetic Peptide-Based Marker Vaccine and Diagnostic System for Effective Control of Porcine Reproductive and Respiratory Syndrome (PRRS)” US Patent Application 14/380,010 (2014), and WO Patent Application PCT/US/2011/068133 (2011).

22. Wang CY and Peng WJ. “Designer Peptide-based PCV2 Vaccine” WO Patent Application PCT/US/2010/041406 (2010).

23. Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang TY, Fang XD, Hung CH, Hutter-Paier B, Windisch M. Site Specific UBITh Amyloid-β Vaccine for Immunotherapy of Alzheimer's Disease. Vaccine 2007; 25:3041-3052.

24. Wang CY, Walfield AM. Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. [Review Article] Vaccine 2005; 23:2049-2056.

25. Hsueh PR, Kao CL, Lee CN, Chen LK, Ho MS, Sia C, Fang XD, Lynn S, et al. and Wang, CY. Highly Specific Severe Acute Respiratory Syndrome Antibody Test for Serosurveillance. Emerg. Infect. Diseases 2004; 10:1558-1562.

26. Wang CY, Lynn S., Jong MH, Lin YL., et al. Appendix 58, Full protection in pigs against FMDV challenge following single dose of synthetic emergency vaccine. In Report of the Session of the Research Group of the Standing Technical Committee of the European Commission for the Control of Foot-and-Mouth Disease. Food and Agricultural Organization, Rome, pp. 365–375, 2004.

27. Finstad CL, Wang CY, Kowalski J, Zhang M, Li ML, Li XM, Xi WG, Bosland MC, Murthy KK, Walfield AM, Zamb TJ. Synthetic Luteinizing Hormone Releasing Hormone (LHRH) vaccine for effective androgen deprivation and its application to Prostate Cancer immunotherapy. Vaccine 2004; 22:1300 1313.

28. Wang CY, Walfield AM, Fang X, Hammerberg B, Ye J, Li ML, Shen F, Shen M, Alexander V and MacGlashan DW. Synthetic IgE peptide vaccine for immunotherapy for Allergy. Vaccine 2003; 21:1580-1590.

29. Wang, CY, Shen M, Tam G, Fang XD, Ye J, Shen F, Walfield AM, Wang JJG, et al. Synthetic AIDS vaccine by targeting HIV receptor. Vaccine 2002; 21:89-97.

30. Wang, CY, Chang TY, Walfield AM, Ye J, Shen M, Chen SP, Li MC, Lin YL, et al. Effective Synthetic peptide vaccine for Foot and Mouth Disease in swine. Vaccine. 2002; 20:2603-2610.

31. Wang, CY, Chang TY, Walfield AM, Ye J, Shen M, Zhang ML, Lubroth J, et al. Synthetic Peptide-based Vaccine and Diagnostic System for Effective Control of Foot and Mouth Disease. Biologicals 2001; 29: 221-228.

32. Wang, CY, Sawyer LSW, Murthy KK, Fang XD, Walfield AM, et al. Postexposure immunoprophylaxis of HIV primary isolates by an antibody to HIV receptor complex. Proc Natl Acad Sci USA 1999; 96:10367-10372.

33. Shen F, Chen PD, Walfield AM, Ye J, House J, Brown F, Wang CY. Differentiation of convalescent animals from those vaccinated against Foot and mouth disease by a peptide ELISA. Vaccine 1999; 17:3039-3049.

34. Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, et al. Controlled release microparticles as a single dose diphtheria toxoid vaccine; immunogenicity in small animal models. Vaccine 1998; 16:346-352.

35. Singh M. Hio C, Qiu H, Li XM, Wang CY, et al. CTL induction using synthetic peptides delivered in emulsions – Critical role of the formulation procedure. Vaccine 1997; 15:1773-1778.

36. Li D, Forrest BD, Li Z, Xue P, Hanson CV, Duan S, Cheng H, Li M, Wang CY, et al. International clinical trials of HIV vaccines: II. Phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China. Asian Pac J Allergy Immunol 1997; 15: 105-113.

37. Phanuphak P. Teeratakulpixarn S, Sarangbin S, Nookhai S, Ubolyam S, Sirivichayakul S, Leesavan A, Forrest BD, Hanson CV, Li ML, Wang, CY, et al. International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac J Allerg Immunol 1997; 15:41-48.

38. Singh M, McGee JP, Li XM, Koff W, Zamb T, Wang CY and O’Hagan DT. Biodegradable microparticles with an entrapped branched octameric peptide as a controlled-release HIV-1 vaccine. J Pharmaceut Sci 1997; 86:1229.

39. Singh M, Li XM, McGee JP, Zamb T, Koff W, Wang CY, O’Hagan DT. Controlled release microparticles as a single dose hepatitis B vaccine; evaluation of immunogenicity in mice. Vaccine 1997; 15:475.

40. Singh M, Li XM, Wang HY, McGee JP, Zamb T, Koff W, Wang CY and O’Hagan DT. Immunogenicity and protection in small-animal models with controlled-release tetanus toxois microparticles as a single-dose vaccine. Infect and Immunity 1997; 65:1716.

41. Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY and O’Hagan D. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996; 14:1523.

42. Hioe CE, Qiu H, Chen PD, Bian Z, Li ML, Li J, Singh M, Kuebler P, McGee O’Hagan D, Zamb T, Koff W, Allsopp C, Wang CY, et al. Comparison of P, adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine 1996; 14:412-418.

43. Quiroga JA, van Binsbergen J, Wang CY, Pardo M, Navas S, Trines C, Herrero M and Carreno V. Immunoglobulin M antibody to hepatitis C virus core antigen: Correlations with viral replication, histological activity, and liver disease outcome. J Hepatol 1995; 11:1635.

44. Prince AM, Brotman B, Inchauspe G, Pascual D. Nasoff M. Hosein B and Wang CY. Patterns and prevalence of hepatitis type C infection in post-transfusion non-A, non-B hepatitis. J Inf Dis 1993; 167: 1296-1301.

45. Sheu JC, Wang JT, Wang TH, Wang CY, et al. Prevalence of hepatitis C viral infection in a community in Taiwan. Detection by synthetic peptide-based assay and polymerase chain reaction. J Hepatol 1993; 17:192.

46. Wang, CY, Looney, P.J., Li, M.L., Walfield, A.M., Ye, J., Hosein, B., Tam, J.P., and Wong-Staal, F. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991; 254:285-288.

47. Hosein B, Fang X and Wang CY. Anti-HCV, anti-GOR, and autoimmunity. Lancet 1992; 339:871.

48. Hosein B, Fang CT, Popvsky MA, Ye J, Zhang M and Wang, CY. Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein. Proc Natl Acad Sci USA. 1991; 88:3647.

49. Hosein B, Present W, Wang CY, and Fang CT. synthetic peptide-based EIAs to distinguish HTLV-I from HTLV-II infection. Transfusion 1990; 30S: 513.

50. Kao HT, Gregerson PK, Tang JC, Takahashi T, Wang CY and Silver J, Molecular analysis of HLA class genes in two DR6w-related haplotypes, DRw13 DQw1 and DRw14 DQw3. J Immunol 1989; 142: 1743.

51. Sung SSJ, Bjorndahl JM, Wang CY, Kao HT and Fu SM. Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by PMA and Anti-CD3 monoclonal antibody. J Exp Med 1988; 167: 937.

52. Sung SSJ, Jung LKL, Walters JA, Chen W, Wang CY, and Fu SM, Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J Exp Med 1988; 168: 1539.

53. Wang CY. Synthetic-peptide-based immunodiagnosis of retrovirus infection: current status and future prospects. In “Synthetic Peptides in Biotechnology”. Edited by A. Mizrahi, Adv. In Biotechnological Processes. 1988; 10:131.

54. Shimazaki C, Wisniewolski D, Scheinberg D, Atzpodien J, Strife A, Gulati S, Fried J,Wisniewolski R, Wang CY and Clarkson B. Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads. Blood 1988; 72:1248-1254.

55. Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY and Carter DM. Expression of HLA-DR molecules by Keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med 1986; 164: 1013.

56. Gregersen PK, Shen M, Song Q, Wang CY, et al. Molecular diversity of HLA-DR4 haplotypes. Proc Natl Acad Sci USA 1986; 83: 2642-2646.

57. Rinnooy-Kan EA, Wright SD, Welte K and Wang CY. Fc receptors on monocytes cause OKT-3 treated lymphocytes to internalize T3 and secrete IL-2. Cell Immunol 1986; 98:181

58. Buskin Y, Posnett DN, Pernis B and Wang CY. A new HLA-linked T cell membrane molecule, related to the beta chain of the clonotypic receptor, is associated with T3. J Exp Med 1986; 164:458.

59. Posnett D, Wang CY and Friedman SM. Inherited polymorphism of the human T cell antigen receptor detected by a monoclonal antibody. Proc Natl. Acad Sci USA 1986; 83:7888.

60. Tse DB, Al-Haiden M, Pernis B, Cantor CR and Wang CY. Intracellular accumulation of T cell receptor complex molecules in a human T leukemia cell line. Science 1986; 234:748.

61. Wang JG, Steel S, Wisniewolski R and Wang CY. Detection of antibodies to HTLV-III using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein. Proc Natl Acad Sci USA 1986; 83:6159.

62. Wang CY, Bushkin Y, Lane CL, McGrath H and Posnett DN. Stimulation and expansion of a human T cell subpopulation by a monoclonal antibody to T cell receptor molecule. Hybridoma 1986; 5:179.

63. Schwarting R, Stein H and Wang CY. monoclonal antibody S-HCL1 and S-HCL3 [also known as Leu 13 and Leu 14] allow the diagnosis of hairy cell leukemia. Blood 1985; 65:974.

64. Bushkin Y, Chorney MJ, Diamante E, Lane CL, Fu SM and Wang, CY. Biochemical characteriazation of a p43, 12 complex: comparison to human and murine class I molecules. Mol Immunol 1985; 22:695.

65. Schwarting R, Welte K, Chiorazzi N, Ralph P, Lane CL, Long CW, and Wang, CY. Biochemical characterization and purification of human B cell stimulatory factory (BSF). Eur J Immunol 1985; 15:632.

66. Wang, CY, Bushkin Y, Chen BPD, Platsoucas C and Long CW. Preparation and characterization of monoclonal antibodies directed against epitopes of Human IFN-y. Hybridoma 1984; 4:321.

67. Bushkin Y, Chorney MJ, Diamante E, Fu SM and Wang, CY. Biochemical characterization of the human T6 antigen; a comparison between T6 and murine TL. Mol. Immunol 1984; 21:821.

68. Posnett DN, Biegler RD, Bushkin Y, Fisher DE, Wang CY, Mayer LF, Chiorazzi N and Kunkel HG. T cell anti-idiotypic antibodies reveal differences between two human leukemias. J Exp Med 1984; 160:499.

69. Posnett DN, Wang CY, Chiorazzi N, Crow MK and Kunkel HG. An antigen characteristic of hairy cell leukemia cells is expressed on certain activated B cells. J immunol 1984; 133:1635.

70. Peng RL, Al-Katib A, Knowles DM, Lu L, Broxmeyer H, Telidjian B, C Hiao JW and Wang CY. Preparation and characterization of monoclonal antibodies recognizing two distinct differentiation antigens Pro-Im1, Pro-Im2 on early hematopoeitic cells. Blood 1984; 64:1169.

71. Rinnooy Kan EA, Platzer E, Welte K, and Wang CY. Modulation induction of The T3 antigen by OKT3 is monocyte dependent. J Immunol 1984; 133:2979.

72. Wang CY, Azzo W, Al-Katib A, Chiorazzi N and Knowles DM. Preparation and characterization of monoclonal antibodies recognizing three distinct differentiation antigens (BL1, BL2, and BL3) on human B lymphocytes. J Immunol 1984; 1133:684.

73. Wang CY, Al-Katib A, Lane CL, Koziner B and Fu, SM. Induction of Leu 10 (HLA-DC/DS) antigen expression by human precursor B cell lines. J Exp Med 1983; 158:1757.

74. Rinnooy Kan EA, Wang CY, Wang LC and Evans RL. Non-covalently bonded subunits of 22KD and 28KD are rapidly internalized by T cells reacted with anti-Leu4 [now termed CD3] antibody. J Immunol 1983; 131:536.

75. Biegler RD, Fisher DE, Wang CY, Rinnooy Kan EA and Kunkel HG. Idiotype-like molecules on cells of a human T-cell leukemia. J Exp Med 1983; 158:1000.

76. Welte K, Platzer EW, Wang CY, Rinnooy Kan EA, Moore MAS and Mertelsmann R. OKT8 [now termed CD8] antibody inhibits OKT3 [now termed CD3]-induced IL-2 production and proliferation of CD8+ cells. Immunol 1983; 131:2356.

77. Knowles DM, Tolidgian B, Maiboe CC, Halper J, Azzo W and Wang CY. A new human B lymphocyte surface antigen (BL2) detected by a monoclonal antibodies: Distribution of benign and malignant lymphoid cells. Blood 1983; 62:191.

78. Venuta S, Mertelsmann R, Welte K, Feldman S, Wang CY and Moore MAS. Production and regulation of Interleukin-2 in human lymphoblastic leukemias studied with T cell monoclonal antibodies. Blood 1983; 61:781.

79. Miki Y, Kishi H, Muragachi A, Maruyama S, Kishimoto S, Yamamura Y, Wang CY and Kishimoto T. Induction of IgG production in a human monoclonal B lymphoblastoid cell line by a B cell-specific monoclonal antibody (BL2). Immunol 1982; 1290: 1921.

80. Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman S and Moore MAS. Purification of human Interleukin-2 to apparent homogeneity and its molecular heterogeneity. J Exp Med 1982; 156:454.

81. Shin HS, Wang CY and Choi YS. Activation of autologous reactive helper T lymphocytes for differentiation of human B lymphocytes. J Immunol 1981;

82. Wang CY, Good RA, Ammirati P, Dymbort G and Evans RL. Identification of a p69/71 complex [now termed Leu 1 or CD5] expressed on human T cells sharing determinants with B type chronic lymphatic leukemia. J Exp Med 1980; 151: 1539.

83. Halper J, Knowles DM and Wang CY. Ia antigen [now termed HLA-DR or class II MHC antigen] expression by human malignant lymphomas: correlation with conventional lymphoid markers. Blood 1980; 55:373.

84. Gottlieb AB, Fu SM, Yu DTY, Wang CY, Halper JP and Kunkel HG. The nature of the stimulation cell in human allogeneic and autologous MLC reaction: Role of isolated IgM-bearing B cells. J Immunol 1979; 123: 1497.

85. Wang, CY, Structural and functional characterization of surface antigens on human B lymphocytes. Ph.D. Thesis, The Rockefeller University, 1979.

86. Wang CY, Fu SM and Kunkel HG. Isolation and immunological characterization of a major surface glycoprotein gp54 [now known as IL6 receptor] preferentially expressed on certain human B cells. J Exp Med 1979; 149:1434.

87. Fu SM, Chiorazzi N, Wang CY, Montazeri CM and Kunkel HG. Ia bearing T cells in man. Their identification and role in the generation of allogeneic helper activity. J Exp Med 1978; 148:1423.

88. Winchester RJ, Wang CY, Gibofsky A, Kunkel HG, Lloyd K and Old, LJ. Expression of Ia-like antigens [now termed HLA-DR or class II MHC antigen] on cultured human malignant melanoma cell lines. Proc Natl. Acad Sci. 1978; 75:6235.

89. Winchester RJ, Meyers PA, Broxmeyer HE, Wang CY, Moore MAS and Kunkel HG. Inhibition of human erythropoietic colony formation in culture by treatment with Ia antisera. J Exp Med 1978; 148:613.

90. Halper JP, Fu SM, Wang CY, Winchester RJ and Kunkel HG. Patterns of expression of human Ia-like antigens [now termed HLA-DR or class II MHC antigen] during the terminal stages of B cell development. J Immunol 1978; 119:1520.

91. Hoffman T, Wang CY, Winchester RJ, Ferarrini M and Kunkel HG. Human lymphocyte bearing Ia-like antigens [now termed HLA-DR or class II MHC antigen]: Absence in patients with infantile Hypogammaglobulinemia. J Immunol 1977; 119:1250.

92. Winchester RJ, Ross, GD, Jarowski CI, Wang CY, Halper J and Broxmeyer HE. Expression of a Ia-like antigen on human granulocytes during early stages of differentiation. Proc Natl Acad Sci USA 1977; 74:4012-4016.

Professional and honorary affiliations

Public speaking

Dr. Chang Yi Wang has been invited to numerous Presentations and Plenary Lectures including:

• Hsinchu, Taiwan National Tsing Hua University Lecture Series: “From Double Helix to Efficacious Vaccines Through Rational Design” April 10, 2010

• Taipei, Taiwan Forum on Vaccine Industry Development in Taiwan, Taiwan Biotech Association: “A Reflection and New Determination: Site Directed Vaccines and Immunotherapeutics” [Plenary Lecture] July 24, 2008

• Vienna, Austria International Atomic Energy Agency (IAEA)/Food and Agriculture Organization (FAO) and Office of International des Epizooties (OIE) World Organization for Animal Health: Use Of Standards and References for Serological And Molecular Tests for Transboundary Diseases In Livestock. November 21–24, 2006

• Montreal, Quebec, Canada 5th World Congress on Vaccines, Immunization & Immunotherapy [Plenary Lecture] November 6–9, 2006

• Dubai, UAE 7th Global Vaccinology Forum on Disease Immunization and Immunotherapy: Site-Specific Peptide Vaccines for Immunotherapy and Immunization and for Veterinary Applications [Plenary Lecture] March 5–7, 2005

• Tokyo, Japan 4th World Congress on Vaccines & Immunization: Site-Specific Peptide Vaccines for Immunotherapy and Immunization Against Chronic Diseases, Cancer, Infectious Disease, and for Veterinary Applications [Plenary Lecture], September 30-October 3, 2004

• Washington, D.C., US-Taiwan Business Council, The Brookings Institution, and the Center for Strategic and International Studies Symposium on The Taiwan Presidential Elections: “Political, Economic, & Security Implications”: Reasons to Choose Taiwan May 6, 2004

• Singapore. Biomedical Asia, Partnering Seminar: UBI as a Rising Star of the Biopharmaceutical Industry November 4, 2003

• San Diego, California Days of Molecular Medicine Symposium: Immunotherapy of Infectious, Chronic Diseases and Cancer by Site-Specific Peptide Vaccines. March 13–15, 2003

• Cambridge, Massachusetts Knowledge Foundation’s International Conference on HIV Vaccines: Synthetic AIDS Vaccine by Targeting HIV Receptor June 22–23, 2003

• Tainan, Taiwan International Symposium on Agricultural Biotechnology, National Cheng Kung University: Site Specific Synthetic Peptide Antigens and Functional Antigenics: Applications to Animal Health. December 13–14, 2002

• Lyon, France Foundation Merieux of International Association of Biologicals Standardization: Immunological Application of Synthetic Peptides. May 9–11, 2001

• Amsterdam, Netherlands IAVI Neutralization Task Force: Immunoprophylaxis, Immunotherapy, and a Synthetic AIDS Vaccine Targeting HIV Receptors. April 25, 2001

• London, England HIV Therapeutics: Searching for the Next Generation: Immunoprophylaxis, Immunotherapy, and a Synthetic AIDS Vaccine Targeting HIV Receptors February. 28-March 1, 2001

• Baltimore, Maryland Maryland Meeting of the Institute of Human Virology: Postexposure Immunoprophylaxis of Primary Isolate by an Antibody to HIV Receptor Complex. September 15, 2000

• Taipei, 2nd Annual Biological World Taiwan: Positioning Taiwan’s Biologics Industry on a Global Map. February 26, 2014

• Yangzhou, Biological Medicine Forum of Yangzhou, China 2018 : 揚州古名城: 21世紀新藥生產重鎮，美台UBI集團領銜起跑. April 25, 2018

UBI Group of Companies

Selected Photos

References

1. ^{{cite web |url=http://www.newsrx.com/newsletters/Medical-Patent-Week/2007-06-17/55061720077MP.html/ |title=United Biomedical, Inc. CEO Dr. Chang Yi Wang named Inventor of the Year 2007 by New York Intellectual Property Law Association |publisher=NewsRx |date=2007-06-17 |accessdate=2011-08-05 |deadurl=yes |archiveurl=https://web.archive.org/web/20110928232530/http://www.newsrx.com/newsletters/Medical-Patent-Week/2007-06-17/55061720077MP.html/ |archivedate=September 28, 2011 |df=mdy-all }}
2. ^{{cite web |url=http://www.unitedbiomedical.com/Cor_Info/Default.asp/ |title=Management Team |publisher=UBI |date= |accessdate=2011-08-05 |deadurl=yes |archiveurl=https://web.archive.org/web/20110607050230/http://www.unitedbiomedical.com/Cor_Info/Default.asp |archivedate=June 7, 2011 |df=mdy-all }}

External links